<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Assertio Therapeutics, Inc.

    Assertio Therapeutics, Inc.

    Assertio Therapeutics is committed to providing responsible solutions to advance p...

    Assertio Therapeutics is committed to providing...

    Filing Type:    PU
    CAVU Biotherapies, Inc.

    CAVU Biotherapies, Inc.

    CAVU Biotherapies offers a comprehensive solution to prepare for, monitor, and tre...

    CAVU Biotherapies offers a comprehensive soluti...

    Filing Type:    CF
    Voyager Therapeutics, Inc.

    Voyager Therapeutics, Inc.

    Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...

    Voyager Therapeutics is developing life-changin...

    Filing Type:    PU
    Prothena Corporation plc

    Prothena Corporation plc

    Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage neuroscience company f...

    Prothena Corporation plc (Nasdaq: PRTA) is a cl...

    Filing Type:    PU
    Eagle Pharmaceuticals, Inc.

    Eagle Pharmaceuticals, Inc.

    Eagle is a specialty pharmaceutical company working to advance safe and efficient ...

    Eagle is a specialty pharmaceutical company wor...

    Filing Type:    PU
    Eloxx Pharmaceuticals, Inc.

    Eloxx Pharmaceuticals, Inc.

    Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developi...

    Eloxx Pharmaceuticals, Inc. is a clinical-stage...

    Filing Type:    PU
    Mersana Therapeutics, Inc.

    Mersana Therapeutics, Inc.

    Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...

    Mersana Therapeutics is a clinical-stage biopha...

    Filing Type:    PU
    Erytech Pharma S.A.

    Erytech Pharma S.A.

    Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...

    Founded in Lyon, France in 2004, ERYTECH is a c...

    Filing Type:    PU
    Delee Corp

    Delee Corp

    At Delee we’re fundamentally changing not only the way cancer is detected but also...

    At Delee we’re fundamentally changing not only ...

    Amount Raised:    $492,503.00
    Fundraising Status:    EC
    Filing Type:    CF
    ©2026 National Investor Network. All Rights Reserved.